Pediatric liver transplantation for acute liver failure. 2007

H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
Department of General Surgery, Baskent University Faculty of Medicine, Ankara, Turkey.

The only proven therapy for patients unlikely to recover from acute liver failure (ALF) is liver transplantation. Correct diagnosis of these individuals and rapid referral to a transplant center are crucial. We evaluated 12 pediatric patients with ALF who underwent liver transplantation (LT) at our institution during a 3-year period. The reasons for transplantation were hepatitis A (3 patients); non-A, non-E hepatitis (3); autoimmune hepatitis (1); fulminant Wilson's disease (3); Amanita phalloides (mushroom) poisoning (1); and hepatitis B and toxic hepatitis with leflunomide treatment (1). Seven of the participants were female and five were male (mean age, 9.1 +/- 4.2 years). Three received right liver-lobe grafts, one received a whole liver graft, and the remainder received left or left-lateral liver lobe grafts. All patients recovered from hepatic coma the second postoperative day. Two patients died at postoperative days 57 and 71 due to adult respiratory distress syndrome and sepsis with multiorgan failure, respectively. One patient required retransplantation because of chronic rejection 7 months after the initial transplantation. That patient died 10 days after retransplantation because of sepsis. Nine patients were healthy at follow-up (range, 2-46 months). LT is the only treatment option for ALF in patients in countries with low organ-donation rates. In this scenario, donor preparation in a limited time frame is difficult. We have been able to decrease the duration of donor preparation to approximately 4 hours (including biopsy of the donated liver tissue).

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D002102 Cadaver A dead body, usually a human body. Corpse,Cadavers,Corpses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000641 Ammonia A colorless alkaline gas. It is formed in the body during decomposition of organic materials during a large number of metabolically important reactions. Note that the aqueous form of ammonia is referred to as AMMONIUM HYDROXIDE.

Related Publications

H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
November 2010, Pediatric transplantation,
H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
June 2022, Journal of pediatric gastroenterology and nutrition,
H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
December 2023, Hepatology international,
H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
February 2012, Best practice & research. Clinical gastroenterology,
H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
April 2017, Cirugia espanola,
H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
May 2018, Clinics in liver disease,
H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
September 1999, European journal of gastroenterology & hepatology,
H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
November 1987, Lancet (London, England),
H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
August 2010, Transplant international : official journal of the European Society for Organ Transplantation,
H Karakayali, and Y Ekici, and F Ozcay, and B Bilezikci, and G Arslan, and M Haberal
November 2022, Journal of pediatric gastroenterology and nutrition,
Copied contents to your clipboard!